Dr. Sergio Martínez Hervás

Principal Investigator
Research Group on Cardiometabolic Risk and Diabetes

Presentation

Dr. Sergio Martínez Hervás is a Senior Lecturer of Medicine at the University of Valencia and assistant physician in charge of the Lipids Unit of the Endocrinology and Nutrition Service at the Hospital Clínico Universitario of Valencia.

His training as a medical internal resident was carried out at the Hospital Clínico Universitario of Valencia. His research work in the field of metabolic disorders and arteriosclerosis began during the MIR training period, with continuity in subsequent years where he obtained a Río Hortega contract, as well as a Bancaja Research grant and a Juan Rodés contract that allowed him to combine a care activity, based on the care of patients diagnosed with metabolic disorders, with training in the laboratory.

He is also a member of the CIBER research group on Diabetes and Associated Metabolic Diseases (CIBERDEM) of the Carlos III Health Institute. His research work has been developed mainly in the area of cardiometabolic risk and diabetes and its associated complications. He is the author of more than 100 original papers and reviews published in different international journals. He has been the principal investigator in 5 research projects financed in competitive public calls, both national and regional. As a collaborator, he has also participated in European projects and national and regional competitive projects.

Dr. Sergio Martínez Hervás
Principal
Investigator
Dr. Sergio Martínez Hervás

sergio.martinez@uv.es  

Publications
Light deficiency in Apoe-/-mice increases atheroma plaque size and vulnerability by modulating local immunity. Hurtado-Genoves G, Herrero-Cervera A, Vinue A, Martin-Vano S, Aguilar-Ballester M, Taberner-Cortes A, Jimenez-Marti E, Martinez-Hervas S, Gonzalez-Navarro H. Biochimica Et Biophysica Acta. Molecular Basis Of Disease. 2024 Feb 8;1870(4):167052. doi: 10.1016/j.bbadis.2024.167052. PMID: 38336102

Comparison of GLP-1 Receptor agonists and other glucose-lowering agents on cardiovascular outcomes in individuals with type 2 diabetes and obesity: a spanish real-world population-based study. Palanca A, Javier Ampudia-Blasco F, Miguel Calderon J, Sauri I, Martinez-Hervas S, Luis Trillo J, Redon J, Real J. Diabetes Research and Clinical Practice. 2023 Dec 22:111071. doi: 10.1016/j.diabres.2023.111071. PMID: 38142748

Low muscle mass is associated with poorer glycemic control and higher oxidative stress in older patients with type 2 Diabetes. Alabadi B, Civera M, De la Rosa A, Martinez-Hervas S, Gomez-Cabrera M, Real J. Nutrients. 2023 Jul 17;15(14):3167. doi: 10.3390/nu15143167. PMID: 37513585

Real-world evaluation of GLP-1 receptor agonist therapy persistence, adherence and therapeutic inertia among obese adults with Type 2 Diabetes. Palanca A, Ampudia Blasco F, Calderon J, Sauri I, Martinez Hervas S, Trillo J, Redon J, Real J. Diabetes Therapy. 2023 Apr;14(4):723-736. doi: 10.1007/s13300-023-01382-9. PMID: 36847952

Vascular smooth muscle cell phenotype is modulated by ligands of the lymphotoxin β receptor and the tumor necrosis factor receptor. Martin-Vano S, Miralles-Abella A, Castano P, Hurtado-Genoves G, Aguilar-Ballester M, Herrero-Cervera A, Vinue A, Martinez-Hervas S, Gonzalez-Navarro H. Clinica e Investigacion en Arteriosclerosis. 2023 Jan-Feb;35(1):1-11. English, Spanish. doi: 10.1016/j.arteri.2022.05.003. PMID: 35738949

A very rare variant in SREBF2, a possible cause of hypercholesterolemia and increased glycemic levels. Garcia-Garcia A, Martinez-Hervas S, Vernia S, Ivorra C, Pulido I, Martin-Escudero J, Casado M, Carretero J, Real J, Chaves F. Biomedicines. 2022 May 19;10(5):1178. doi: 10.3390/biomedicines10051178. PMID: 35625914

Association of chemokines IP-10/CXCL10 and I-TAC/CXCL11 with insulin resistance and enhance leukocyte endothelial arrest in obesity. Moreno B, Hueso L, Ortega R, Benito E, Martinez Hervas S, Peiro M, Civera M, Sanz MJ, Piqueras L, Real JT. Microvascular Research. 2022 Jan;139:104254. doi: 10.1016/j.mvr.2021.104254. PMID: 34534571

Beneficial effects of PCSK9 inhibition with alirocumab in familial hypercholesterolemia involve modulation of new immune players. Marques P, Domingo E, Rubio A, Martinez-Hervas S, Ascaso JF, Piqueras L, Real JT, Sanz MJ. Biomedicine & Pharmacotherapy. 2022 Jan;145:112460. doi: 10.1016/j.biopha.2021.112460. PMID: 34864314

Comprehensive management of risk factors in peripheral vascular disease. Expert consensus. Barrios V, Beato P, Brotons C, Campuzano R, Merino-Torres J, Mostaza J, Plana N, Rubio J, Comellas M. Revista Clinica Espanola. 2022 Feb;222(2):82-90. doi: 10.1016/j.rceng.2020.11.011. PMID: 34217671

Corticotroph cell hyperplasia as a rare cause of ACTH-dependent Cushing syndrome. Ferri J, Martinez-Ibanez J, Terradez L, Savall E, Martinez-Hervas S, Oller M, Lorente R, Ascaso J, Real J. Endocrinologia, Diabetes y Nutrición. 2022 Nov;69(9):694-701. doi: 10.1016/j.endien.2022.11.004. PMID: 36470644

Developing a simple and practical decision model to predict the risk of incident type 2 diabetes among the general population: The Di@bet.es Study. Martinez-Hervas S, Morales-Suarez-Varela MM, Andres-Blasco I, Lara-Hernandez F, Peraita-Costa I, Real JT, Garcia-Garcia AB, Chaves FJ. European Journal of Internal Medicine. 2022 Aug;102:80-87. doi: 10.1016/j.ejim.2022.05.005. PMID: 35570127

Effect of personality on blood glucose control in patients with type 1 diabetes. Gu Hong W, Ferri J, Ampudia-Blasco F, Martin-Brufau R, Peiro M, Benito E, Martinez-Hervas S, Sanz M, Real J. Endocrinologia, Diabetes y Nutricion. 2022 Nov;69(9):677-685. doi: 10.1016/j.endien.2021.11.034. PMID: 36470643

Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: the pan-European retrospective observational study. D’Erasmo L, Steward K, Cefalu A, Di Costanzo A, Boersma E, Bini S, Arca M, van Lennep J, Real Collado J, Italian and European Working Group on Lomitapide in HoFH. European Journal of Preventive Cardiology. 2022 May 5;29(5):832-841. doi: 10.1093/eurjpc/zwab229. PMID: 34971394

Efficacy of long-term treatment of autosomal recessive hypercholesterolemia with lomitapide: a subanalysis of the Pan-European Lomitapide Study. D’Erasmo L, Giammanco A, Suppressa P, Pavanello C, Iannuzzo G, Di Costanzo A, Tramontano D, Minicocci I, Bini S, Vogt A, Stewards K, Van Lennep J, Bertolini S, Arca M. Frontiers in Genetics. 2022 Aug 22;13:937750. doi: 10.3389/fgene.2022.937750. PMID: 36072671

First clinical and efficacy data on evolocumab in routine clinical practice in endocrinology and nutrition services in Spain: a retrospective observational study (RETOSS-ENDO). Pérez Pérez A, Ortega Martínez de Victoria E, Arrieta Blanco F, Caixàs Pedragós A, Santos Mazo E, Fernandez-Catalina P, Martínez-Hervas S, López-Medina JA, Suárez-Gutiérrez L, Urgeles Planelles JR, Gatell Menchén S, Tinahones Madueño F. Endocrinologia, Diabetes y Nutrición. 2022 Aug-Sep;69(7):540-542. doi: 10.1016/j.endien.2021.07.002. PMID: 35995680

Novel therapies for cardiometabolic disease: recent findings in studies with hormone peptide-derived G protein coupled receptor agonists. Jimenez-Marti E, Hurtado-Genoves G, Aguilar-Ballester M, Martinez-Hervas S, Gonzalez-Navarro H. Nutrients. 2022 Sep 13;14(18):3775. doi: 10.3390/nu14183775. PMID: 36145148

SEA 2022 standards for global control of cardiovascular risk. Mostaza J, Pinto X, Armario P, Masana L, Real J, Valdivielso P, Arrobas-Velilla T, Baeza-Trinidad R, Calmarza P, Cebollada J, Civera-Andres M, Cuende Melero J, Diaz-Diaz J, Fernandez Pardo J, Guijarro C, Jerico C, Laclaustra M, Lahoz C, Lopez-Miranda J, Martinez-Hervas S, Muniz-Grijalvo O, Paramo J, Pascual V, Pedro-Botet J, Perez-Martinez P, Plana N, Puzo J, Sanchez Chaparro M, Vila L. Clinica e Investigacion en Arteriosclerosis. 2022 May-Jun;34(3):130-179. doi: 10.1016/j.arteri.2021.11.003. PMID: 35090775

Anthropometric indicators as a tool for diagnosis of obesity and other health risk factors: a literature review. Piqueras P, Ballester A, Dura-Gil J, Martinez-Hervas S, Redon J, Real J. Frontiers in Psychology. 2021 Jul 9;12:631179. doi: 10.3389/fpsyg.2021.631179. PMID: 34305707

Dissecting abdominal aortic aneurysm is aggravated by genetic inactivation of LIGHT (TNFSF14). Herrero-Cervera A, Espinos-Estevez C, Martin-Vano S, Taberner-Cortes A, Aguilar-Ballester M, Vinue A, Piqueras L, Martinez-Hervas S, Gonzalez-Navarro H. Biomedicines. 2021 Oct 22;9(11):1518. doi: 10.3390/biomedicines9111518. PMID: 34829747

Frailty is associated with oxidative stress in older patients with Type 2 Diabetes. Alabadi B, Civera M, De la Rosa A, Martinez-Hervas S, Gomez-Cabrera MC, Real JT. Nutrients. 2021 Nov 9;13(11):3983. doi: 10.3390/nu13113983. PMID: 34836238

Hypercholesterolemic patients have higher eryptosis and erythrocyte adhesion to human endothelium independently of statin therapy. Cilla A, Lopez-Garcia G, Collado-Diaz V, Blanch-Ruiz MA, Garcia-Llatas G, Barbera R, Martinez-Cuesta MA, Real JT, Alvarez A, Martinez-Hervas S. International Journal of Clinical Practice. 2021 Nov;75(11):e14771. doi: 10.1111/ijcp.14771. PMID: 34473881

Oral unsaturated fat load impairs postprandial systemic inflammation in primary hypercholesterolemia patients. Collado A, Domingo E, Marques P, Perello E, Martínez-Hervás S, Piqueras L, Ascaso JF, Real JT, Sanz MJ. Frontiers in Pharmacology. 2021 Apr 20;12:656244. doi: 10.3389/fphar.2021.656244. PMID: 33959024

Peripheral blood levels of CXCL10 are a useful marker for diabetic polyneuropathy in subjects with type 2 diabetes. Ascaso P, Palanca A, Martinez-Hervas S, Sanz MJ, Ascaso JF, Piqueras L, Real JT. International Journal of Clinical Practice. 2021 Aug;75(8):e14302. doi: 10.1111/ijcp.14302. PMID: 33930221

Postprandial triglyceridemia is modulated by insulin resistance but not by grade of obesity in abdominal and morbid obese subjects. Moreno-Perez B, Benito E, Civera M, Alabadi B, Martinez-Hervas S, Peiro M, Gonzalez-Navarro H, Piqueras L, Jesus Sanz M, Ascaso J, Real J. International Journal of Clinical Practice. 2021 Apr;75(4):e13776. doi: 10.1111/ijcp.13776. PMID: 33089594

Therapies for the Treatment of Cardiovascular Disease Associated with Type 2 Diabetes and Dyslipidemia. Aguilar-Ballester M, Hurtado-Genoves G, Taberner-Cortes A, Herrero-Cervera A, Martinez-Hervas S, Gonzalez-Navarro H. International Journal Of Molecular Sciences. 2021 Jan 11;22(2):660. doi: 10.3390/ijms22020660. PMID: 33440821

Projects
Reference: PI22/00062
Title: Identificación de nuevas dianas terapéuticas y mecanismos de la modulación de la inflamación en las enfermedades metabólicas
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Herminia González Navarro, Sergio Martínez Hervás
Duration: 2023 – 2025
Total budget: 147.620,00 €
Reference: ICI21/00020
Title: Evaluación de la eficacia de la farmacogenética para mejorar la respuesta al tratamiento en sujetos con diabetes tipo 2 insuficientemente controlada
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Sergio Martínez Hervás
Duration: 2022 – 2025
Total budget: 267.300 €
Reference: PMP21/00076
Title: ImpactT2D: una estrategia genómica para implementar medicina de precisión en la diabetes tipo 2
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Felipe Javier Chaves Martínez
Duration: 2022 – 2025
Total budget: 106.700 €
Reference: PROMETEO/2019/032
Title: Una aproximación traslacional desde la clínica a la experimentación animal: Estudio del papel del eje CCL11/CCR3 y la inflamación eosinofílica en la patología cardiovascular asociada a desórdenes metabólicos
Funding body: Conselleria de Educación, Cultura y Deporte
Principal Investigator: Mª Jesús Sanz Ferrando
Duration: 2020 – 2023
Total budget: 211.736 €
Reference: PI19/00169
Title: Papel de los procesos inflamatorios en las enfermedades metabólicas y en las complicaciones asociadas
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Herminia González Navarro, Sergio Martínez Hervás
Duration: 2020 – 2022
Total budget: 159.720 €
+ Info
Have the Government’s prescription algorithm and the 2013 American College of Cardiology/American Heart Association guidelines for managing dyslipidaemia influenced the management of dyslipidaemia?. The MEJORALO-CV Project. Giner Galvan V, Bonig Trigueros I, Facila Rubio L, Morillas Blasco P, Martinez Hervas S, Pascual Fuster V, Valls Roca F, Soler Portmann C, Tamarit Garcia J, Pallares Carratala V, Componentes del grupo de Trabajo MEJORALO-CV. Revista Clinica Espanola. 2020;220(5):282-289. doi: 10.1016/j.rce.2019.08.006. PMID: 31744620

Title: Estudio de nuevos mecanismos angiogénicos e inflamatorios asociados a la obesidad
Doctoral candidate: Hueso Soler, Luisa María
Director(s): Piqueras Ruiz, Laura; Real Collado, Jose Tomás; Sanz Ferrando, María Jesús
Date of the defense: 28/04/2023
University: Universitat de València

Title: La ecografía Doppler con flujo en color en el diagnóstico, tratamiento y pronóstico de la enfermedad de Graves-Basedow
Doctoral candidate: Rubio Puchol, Olalla
Director(s): Merchante Alfaro, Agustín Ángel; Martínez Hervás, Sergio
Date of the defense: 25/01/2022
University: Universitat de València